NEWARK, Calif., Nov. 30, 2020 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company
will host a conference call to provide a research and development
(R&D) and Corporate update at 8:30 a.m.
EST on December 9, 2020. The
call will include the Protagonist management team and Andrew Kuykendall, M.D., an investigator in the
PTG-300 Phase 2 study and a member of the Department of Malignant
Hematology at the Moffitt Cancer Center.
To access the live call, dial 1-844-515-9178 (U.S./Canada) or 1-614-999-9313 (international) and
refer to conference ID number 8794865. A live and archived webcast
will also be accessible in the Investors section of the Company's
website at www.protagonist-inc.com.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based therapeutics to address significant
unmet medical needs and transform existing treatment paradigms for
patients. PTG-300 is an injectable hepcidin mimetic in development
for the treatment of polycythemia vera and other blood disorders.
PTG-200 is an orally delivered, gut-restricted, interleukin-23
receptor specific antagonist peptide in development for the
treatment of inflammatory bowel disease, with Crohn's disease as
the initial indication. In addition to PTG-200, two oral peptide
interleukin-23 receptor antagonist candidates from a collaboration
with Janssen Biotech, Inc., are in development and have been
selected for advancement into clinical studies. PN-943 is an orally
delivered, gut-restricted alpha-4-beta-7 integrin specific
antagonist peptide in development for the treatment of inflammatory
bowel disease, with ulcerative colitis as the initial targeted
indication.
Protagonist is headquartered in Newark, California. For further information,
please visit www.protagonist-inc.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/protagonist-to-host-conference-call-and-webcast-to-provide-a-research-update-on-december-9-2020-301180069.html
SOURCE Protagonist Therapeutics, Inc.